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Inflammation contributes to the development of type 2 diabe-
tes and associated complications [1]. The inflammatory path-
ways activated by metabolic stress promote the secretion of 
pro-inflammatory cytokines and attract immune-inflammato-
ry cells (e.g., macrophages and lymphocytes) into inflamed tis-
sues. Subsequently, initiated inflammatory signals impair insu-
lin action in insulin-responsive tissues such as the liver and 
skeletal muscles, inducing systemic insulin resistance through-
out the body.
  Thiazolidinediones (TZD), which are used as anti-diabetic 
drugs, are agonists for peroxisome proliferator-activated recep-
tor gamma (PPARγ), a nuclear transcription factor primarily 
involved in insulin action, lipid and glucose metabolism and 
energy homeostasis [2,3]. Several lines of evidence indicate that 
TZD can improve inflammation in peripheral tissues including 
muscle via the inhibition of specific pro-inflammatory signaling 
pathways (e.g., inhibitors of kappa B kinase beta/nuclear factor-
kappa B [NF-κB]) [4-6], but the anti-inflammatory effects of 
TZD on skeletal muscle have not been extensively investigated. 
  The June issue of Korean Diabetes J included an important 
study by Lee et al. [7] on the effect of rosiglitazone (RGZ) on 
skeletal muscle inflammation in a rat model of moderate obe-
sity and type 2 diabetes. The authors used Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats as a rodent model of type 2 di-
abetes and demonstrated that RGZ administration results in 
the attenuation of diabetes and skeletal muscle inflammation. 
Interestingly, skeletal muscle inflammation was shown to be 
attenuated by the inhibition of two inflammatory pathways, 
ERK1/2 and NF-κB. We fully agree that RGZ improves insulin 
resistance in part due to anti-inflammatory effects in skeletal 
muscle as well as other peripheral tissues, and that the anti-in-
flammatory effects of RGZ are likely mediated by the suppres-
sion of pro-inflammatory cytokines and pathways. However, 
one issue that attracted our attention is that plasma free fatty 
acid (FFA) concentrations were lower in OLETF rats than in 
Long-Evans Tokushima Otsuka (LETO) rats although there is 
no alteration in plasma FFAs with RGZ treatment in OLETF 
rats. The current knowledge, as reflected in previous publica-
tions regarding skeletal muscle inflammation, is that excessive 
influx of FFA into skeletal muscle leads to pro-inflammatory 
states in skeletal muscle that in turn exert detrimental effects 
on insulin sensitivity [8,9]. Without the excessive influx of FFA 
from the systemic circulation into skeletal muscle, it is unclear 
what triggers the pro-inflammatory state in obese and insulin 
resistant OLETF rats. There may be a possible explanation that 
systemic glucose toxicity in OLETF rats can induce pro-inflam-
matory states regardless of the absence of excessive FFA influx. 
To explain this, it would be helpful to analyze other lipid pro-
files such as triglycerides and total cholesterol. With respect to 
no significant effects on homeostasis model assessment-insu-
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lin resistance (HOMA-IR) and HOMA-β (HOMA beta cell 
function) values, the RGZ-mediated improvement in plasma 
glucose and insulin was enough to confirm the anti-diabetic 
effect of RGZ because HOMA-IR and HOMA-β are not vali-
dated to assess insulin sensitivity and beta-cell function in a 
rodent model.
  The study by Lee et al. showed that RGZ attenuated the det-
rimental positive feedback cycle between uncontrolled pro-in-
flammatory states and hyperglycemia, resulting in the improve-
ment in diabetes and skeletal muscle inflammation. Addition-
al studies are needed to understand the mechanisms by which 
RGZ contributes to the improvement of skeletal muscle inflam-
mation, especially to identify main regulatory pathways for anti-
inflammatory effects of RGZ on skeletal muscles. In addition 
to confirming previous observations, we believe that the study 
by Lee et al. extends our understanding about RGZ’s anti-in-
flammatory actions and its contribution to the improvement 
in insulin resistance and diabetes. 
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